Clinical and Translational Medicine, Год журнала: 2024, Номер 14(9)
Опубликована: Сен. 1, 2024
Язык: Английский
Drug Resistance Updates, Год журнала: 2025, Номер 79, С. 101212 - 101212
Опубликована: Фев. 10, 2025
Язык: Английский
Процитировано
1
Biomarker Research, Год журнала: 2024, Номер 12(1)
Опубликована: Сен. 27, 2024
Abstract DNA damage response (DDR) deficiency has been one of the emerging targets in treating breast cancer recent years. On hand, DDR coordinates cell cycle and signal transduction, whose dysfunction may lead to apoptosis, genomic instability, tumor development. Conversely, is an intrinsic feature tumors that underlies their treatments inflict damage. In this review, we systematically explore various mechanisms DDR, rationale research advances DDR-targeted drugs cancer, discuss challenges its clinical applications. Notably, poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated favorable efficacy safety with high homogenous recombination (HRD) status a series trials. Moreover, several studies on novel DDR-related molecules are actively exploring target become resistant PARP inhibition. Before further application new regimens or drugs, standardized biomarkers needed develop for accurately characterizing benefit population predicting efficacy. Despite promising treatments, off-target toxicity drug resistance need be addressed. Strategies overcome await exploration mechanisms, combined targeted immunotherapy will hopefully provide more precise strategies expand potential responsive populations.
Язык: Английский
Процитировано
7
Pathology - Research and Practice, Год журнала: 2025, Номер 269, С. 155864 - 155864
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Heliyon, Год журнала: 2024, Номер 10(19), С. e38310 - e38310
Опубликована: Сен. 23, 2024
Язык: Английский
Процитировано
3
MedComm, Год журнала: 2023, Номер 4(6)
Опубликована: Дек. 1, 2023
Abstract The rapid advancement of tumor immunotherapies poses challenges for the tools used in cancer immunology research, highlighting need highly effective biomarkers and reproducible experimental models. Current immunotherapy encompass surface protein markers such as PD‐L1, genetic features microsatellite instability, tumor‐infiltrating lymphocytes, liquid biopsy circulating DNAs. Experimental models, ranging from 3D vitro cultures (spheroids, submerged air–liquid interface organ‐on‐a‐chips) to advanced bioprinting techniques, have emerged valuable platforms investigations biomarker research. By preserving native immune components or coculturing with exogenous cells, these models replicate microenvironment vitro. Animal like syngeneic genetically engineered patient‐derived xenografts provide opportunities study vivo tumor‐immune interactions. Humanized animal further enable simulation human‐specific microenvironment. Here, we a comprehensive overview advantages, limitations, prospects different specifically focusing on role predicting outcomes ability integrating cutting‐edge this review serves resource accessing forefront investigation.
Язык: Английский
Процитировано
8
MedComm – Oncology, Год журнала: 2024, Номер 3(3)
Опубликована: Сен. 1, 2024
Abstract Not all patients can benefit from chemotherapy due to the various of tumor type, stage, location, and different distribution immune cells in microenvironment (TIME). Immune are widely involved every step cancer progression, including escape, metastasis, drug response, prognosis. In this study, we explored transcriptome data 10 solid tumors treated with identify role cells. We downloaded mutation cancers TCGA databases, used ESTIMATE CIBERSORT algorithms assess proportion TIME. According specific cell infiltration (SICI) CD8 + T M1 macrophages group patients, found that compared SICI low medium groups, high had a larger burden, more gene mutations targeted drugs, activation checkpoints (PD‐1, PD‐L1, CTLA‐4, LAG‐3, TIM‐3, TIGIT), molecules (CD8a, CD80, CD86, TLR2, HLA‐A, HLA‐B, CD11a) ( p < 0.05). Therefore, select an appropriate treatment for by clarifying
Язык: Английский
Процитировано
1
MedComm – Oncology, Год журнала: 2024, Номер 3(4)
Опубликована: Ноя. 4, 2024
Abstract Gastric cancer (GC) ranks among the leading causes of cancer‐related mortality globally. Often, its initial stages manifest subtly, and infrequency routine screenings contributes to late diagnoses in many cases. Systemic treatments for GC include chemotherapy, targeted therapy, immunotherapy, which immunotherapy is first‐line standard treatment advanced GC. In recent years, has seen notable advancements, as evidenced by Food Drug Administration's approval drugs such nivolumab pembrolizumab treatment. Additionally, several other are currently under rigorous preclinical clinical investigation. This review aims shed light on advancements GC, particularly emphasizing insights gained from phase 2/3 trials that assess efficacy, safety, promise various immunotherapeutic modalities, including immune checkpoint inhibitors, CAR‐T‐cell therapies, vaccines, enhancing patient outcomes. Moreover, this delves into intricate immunological framework focusing tumor microenvironment, interactions cells, roles checkpoints PD‐L1. We also address hurdles prospective paths forward realm offering fresh viewpoints potential therapeutic approaches evolving domain.
Язык: Английский
Процитировано
1
Clinical and Translational Medicine, Год журнала: 2024, Номер 14(9)
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
0